| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 05/07/2013 | US8435537 System for the expression of peptides on the bacterial surface |
| 05/07/2013 | US8435536 Fish vaccine |
| 05/07/2013 | US8435535 Fusion proteins of HIV regulatory/accessory proteins |
| 05/07/2013 | US8435534 Cancer immunotherapy |
| 05/07/2013 | US8435533 Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of Chlamydia |
| 05/07/2013 | US8435532 Use of modified extracellular matrix proteins in diagnosis and treatment of atherosclerosis |
| 05/07/2013 | US8435531 Method of treating cancer cells to create a modified cancer cell that provokes an immunogenic response |
| 05/07/2013 | US8435530 Methods for suppressing activity of activated interferon-producing cells |
| 05/07/2013 | US8435529 Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy |
| 05/07/2013 | US8435528 Cytotoxic agents comprising new maytansinoids |
| 05/07/2013 | US8435527 Purification method which prevents denaturation of an antibody |
| 05/07/2013 | US8435526 Methods of treating mucositis using anti-TNF antibodies |
| 05/07/2013 | US8435525 FGF modulation of in vivo antibody production and humoral immunity |
| 05/07/2013 | US8435524 Human cytomegalovirus neutralizing antibodies and use thereof |
| 05/07/2013 | US8435523 Antibodies against nerve growth factor (NGF) with enhanced in vivo stability |
| 05/07/2013 | US8435522 Humanized antibodies against CXCR3 |
| 05/07/2013 | US8435521 Pharmaceutical compositions capable of inducing apoptosis in tumour cells, useful for diagnosis and treatment of B-chronic lymphocytic leukaemia |
| 05/07/2013 | US8435520 Combinations of immunosuppressive agents for the treatment or prevention of graft rejections |
| 05/07/2013 | US8435519 Antibodies that bind alpha subunit of sodium potassium ATPase |
| 05/07/2013 | US8435518 Methods of using IL-17 receptor a antibodies |
| 05/07/2013 | US8435517 Compositions and methods for treating IgE-mediated disorders |
| 05/07/2013 | US8435516 Cancer treatment |
| 05/07/2013 | US8435515 Poly-N-acetyl glucosamine (PNAG/dPNAG)-binding peptides and methods of use thereof |
| 05/07/2013 | US8435514 Method for the treatment of neurodegenerative diseases |
| 05/07/2013 | US8435513 NOTCH1 receptor antibodies and methods of treatment |
| 05/07/2013 | US8435512 Anti-properdin antibodies |
| 05/07/2013 | US8435511 Anti-hepsin antibodies and methods using same |
| 05/07/2013 | US8435510 Platelet derived growth factor receptor supports cytomegalovirus infectivity |
| 05/07/2013 | US8435506 Attenuated FNR deficient enterobacteria |
| 05/07/2013 | US8435495 Characterization of granulocytic Ehrlichia and methods of use |
| 05/07/2013 | US8435494 Mesothelin antibody protein fusions and methods of use |
| 05/07/2013 | CA2572555C Fusion protein of porcine reproductive and respiratory syndrome virus as prrs vaccine |
| 05/07/2013 | CA2560185C Novel assay for the separation and quantification of hemagglutinin antigens |
| 05/07/2013 | CA2530363C Carrier proteins for vaccines |
| 05/07/2013 | CA2478125C Avian cell lines for the production of useful substances |
| 05/07/2013 | CA2475073C Hypoallergenic polypeptides based on fish parvalbumin |
| 05/07/2013 | CA2397030C Methods for treating pancreatic disorders |
| 05/07/2013 | CA2360347C Improved expression of hiv polypeptides and production of virus-like particles |
| 05/02/2013 | WO2013063613A2 Methods and compositions related to intracellular neutralization by igg |
| 05/02/2013 | WO2013063536A1 Actriib binding agents and uses thereof |
| 05/02/2013 | WO2013063516A1 Humanized antibodies that recognize alpha-synuclein |
| 05/02/2013 | WO2013063510A1 Protein formulations containing amino acids |
| 05/02/2013 | WO2013063498A1 Cd44 monoclonal antibody for the treatment of b-cell chronic lymphocytic leukemia and other hematological malignancies |
| 05/02/2013 | WO2013063435A1 Histone deacetylase (hdac) inhibitors for treatment of post-surgical adhesions |
| 05/02/2013 | WO2013063395A1 Humanized antibodies to inkt |
| 05/02/2013 | WO2013063388A1 Diatom-based vaccines |
| 05/02/2013 | WO2013063312A1 Free psa antibodies as diagnostics, prognostics and therapeutics for prostate cancer |
| 05/02/2013 | WO2013063284A1 Antibody formulations and methods |
| 05/02/2013 | WO2013063248A1 Vaccines and methods for creating a vaccine for inducing immunity to all dengue virus serotypes |
| 05/02/2013 | WO2013063229A1 Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells |
| 05/02/2013 | WO2013063110A1 Bispecific immunobinders directed against tnf and il-17 |
| 05/02/2013 | WO2013063095A1 Immunobinders directed against sclerostin |
| 05/02/2013 | WO2013063086A1 Compositions and methods for treatment of proteinopathies |
| 05/02/2013 | WO2013063059A1 Plastid-expressed mycobacterium tuberculosis vaccine antigens esat-6 and mtb72f fused to cholera toxin b subunit |
| 05/02/2013 | WO2013063001A1 Therapeutic combinations and methods of treating melanoma |
| 05/02/2013 | WO2013062083A1 Cancer stem cell-specific molecule |
| 05/02/2013 | WO2013061353A1 Use of mycobacterium avium paratuberculosis peptides to diagnose type 1 diabetes |
| 05/02/2013 | WO2013061273A1 A modified effector cell (or chimeric receptor) for treating disialoganglioside gd2 -expressing neoplasia |
| 05/02/2013 | WO2013061163A2 Tdp-43 specific binding molecules |
| 05/02/2013 | WO2013061112A1 Use of egfl7 modulators for promoting or inhibiting migration of immune cells across vascular endothelium |
| 05/02/2013 | WO2013061056A1 Vaccine |
| 05/02/2013 | WO2013060872A1 Anticancer combination therapy |
| 05/02/2013 | WO2013059876A1 A method of treating mucus hypersecretion |
| 05/02/2013 | WO2013036902A4 Submicron particles to decrease transfusion |
| 05/02/2013 | WO2013036850A3 Modulation of midbody derivatives |
| 05/02/2013 | WO2013036745A3 Ipnv-isav bivalent vaccine using a virus-like particle-based platform and methods of using the same |
| 05/02/2013 | WO2013021279A3 Highly galactosylated antibodies |
| 05/02/2013 | WO2013016468A3 Compositions and methods for improving potency and breadth or hiv antibodies |
| 05/02/2013 | WO2013004234A3 Methods for producing liposomes |
| 05/02/2013 | WO2012169735A9 Complex comprising water-soluble fragments of fcεri and composition comprising same for treating allergic diseases mediated by ige |
| 05/02/2013 | WO2012106356A3 Virus-like particles and methods of use |
| 05/02/2013 | US20130111614 Methods and materials for reducing cardiac xenograft rejection |
| 05/02/2013 | US20130110249 Anti-glucosaminidase passive immunization for staphylococcus aureus infections |
| 05/02/2013 | US20130109838 Method of altering the binding specificity of plasma proteins by oxidation-reduction |
| 05/02/2013 | US20130109057 Method for immunizing animal, composition for immunization, method for producing antibody, method for producing hybridoma, and method for producing monoclonal antibody |
| 05/02/2013 | US20130108692 Compositions and methods for treating influenza |
| 05/02/2013 | US20130108667 Method, apparatus and system for electroporation |
| 05/02/2013 | US20130108663 Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and their use in vaccination |
| 05/02/2013 | US20130108661 Methods and compositions for cancer immunotherapy using flagellin-tumor associated antigen fusion protein expressing tumor cells |
| 05/02/2013 | US20130108660 Anti-trypanosome therapeutic and diagnostic applications |
| 05/02/2013 | US20130108659 Protein-based streptococcus pneumoniae vaccine |
| 05/02/2013 | US20130108657 Conditional superagonist ctl ligands for the promotion of tumor-specific ctl responses |
| 05/02/2013 | US20130108656 Peptide and method for reducing the phosphate requirement and excretion from farm animals |
| 05/02/2013 | US20130108652 Asthma diagnosis using the neuropilin-1 gene, and method for screening for a therapeutic agent for asthma |
| 05/02/2013 | US20130108650 Actriib binding agents and uses thereof |
| 05/02/2013 | US20130108649 Modulation of ul24 interactions with protein targets and uses thereof for inhibition of herpesvirus infection |
| 05/02/2013 | US20130108646 Optimized degenerative muscle disease diagnostics and treatments |
| 05/02/2013 | US20130108645 Methods for enhancing axonal regeneration |
| 05/02/2013 | US20130108643 Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases |
| 05/02/2013 | US20130108641 Anti-gitr antibodies |
| 05/02/2013 | US20130108637 Therapeutic agent for fibromyalgia containing etanercept |
| 05/02/2013 | US20130108634 Etanercept Formulations Stabilized with Meglumine |
| 05/02/2013 | US20130108633 Etanercept Formulations Stabilized with Metal Ions |
| 05/02/2013 | US20130108632 Etanercept Formulations Stabilized with Amino Acids |
| 05/02/2013 | US20130108630 Amino acyl trna synthetases for modulating inflammation |
| 05/02/2013 | US20130108628 Method for treating cancer pain and/or rescuing analgesic effect of morphine treatment of cancer pain |
| 05/02/2013 | US20130108626 Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer |
| 05/02/2013 | US20130108625 Treatment of multiple sclerosis (ms) |
| 05/02/2013 | US20130108621 ANTI-CD154 ANTIBODIES HAVING IMPAIRED FcR BINDING AND/OR COMPLEMENT BINDING PROPERTIES AND THE USE THEREOF IN IMMUNE THERAPIES |
| 05/02/2013 | US20130108620 Methods of treatment using anti-erbb antibody-maytansinoid conjugates |